Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03451331
Title Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Matthew Galsky
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland 21287 United States Details
John Theuer Cancer Center Hackensack New Jersey 07601 United States Details
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903 United States Details
Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center New York New York 10029 United States Details
Vanderbilt-Ingram Cancer Center Nashville Tennessee 37232 United States Details
Huntsman Cancer Institute University of Utah Salt Lake City Utah 84112 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field